Menu
SAB to guide company’s rapid development of differentiated therapeutics and vaccines to address a range of respiratory diseases including COVID-19
Transaction supports development of AuraVax’s lead COVID-19 intranasal program, plus other vaccines and therapeutics targeting respiratory diseases
Transaction bolsters development of AuraVax’s lead COVID-19 intranasal vaccine and strengthens platform for therapeutic development targeting a range of viral infections
Exclusive Option Agreement Covers Inhalation Vaccine Developed by UH Professor